LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC).
Saved in:
| Title: | LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). |
|---|---|
| Authors: | Moore, K.N.1 (AUTHOR), Bookman, M.2 (AUTHOR), Sehouli, J.3 (AUTHOR), Miller, A.4 (AUTHOR), Anderson, C.5 (AUTHOR), Scambia, G.6 (AUTHOR), Myers, T.7 (AUTHOR), Taskiran, C.8 (AUTHOR), Robison, K.9 (AUTHOR), Maenpaa, J.10 (AUTHOR), Willmott, L.J.11 (AUTHOR), Colombo, N.12 (AUTHOR), Thomes-Pepin, J.13 (AUTHOR), Gold, M.A.14 (AUTHOR), Aghajanian, C.15 (AUTHOR), Wu, F.16 (AUTHOR), Molinero, L.17 (AUTHOR), Khor, V.18 (AUTHOR), Lin, Y.G.18 (AUTHOR), Pignata, S.19 (AUTHOR) |
| Source: | Annals of Oncology. 2020 Supplement 4, Vol. 31, pS1161-S1162. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
